OXSONICS THERAPEUTICS
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers. The approach ha... s been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time. The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics is based in Oxford in the UK. For more information please visit: www.oxsonics.com.
OXSONICS THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Device
Founded:
2013-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.oxsonics.com
Total Employee:
11+
Status:
Active
Contact:
+4401865784777
Total Funding:
24.7 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Global Site Tag
Similar Organizations
Airify
Airify is a crowd-sourcing platform for air quality data.
Bicycle Therapeutics
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Chronolife
Chronolife builds predictive medical solutions to aid in diagnosis through a wireless, wearable technology.
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
Instylla
Instylla’s focus is to leverage hydrogel technology .
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Oxford Technology Management
Oxford Technology Management investment in Series B - OxSonics Therapeutics
Perivoli Innovations
Perivoli Innovations investment in Series B - OxSonics Therapeutics
Winton Ventures
Winton Ventures investment in Series B - OxSonics Therapeutics
ForumOxford (at the University of Oxford)
ForumOxford (at the University of Oxford) investment in Series B - OxSonics Therapeutics
Longwall Venture Partners
Longwall Venture Partners investment in Series B - OxSonics Therapeutics
Innovate UK
Innovate UK investment in Grant - OxSonics Therapeutics
Official Site Inspections
http://www.oxsonics.com
- Host name: 5.207.195.35.bc.googleusercontent.com
- IP address: 35.195.207.5
- Location:
- Latitude: 47
- Longitude: 8
- Timezone: Europe/Vaduz
More informations about "OxSonics Therapeutics"
About us - OxSonics Therapeutics
OxSonics was founded in 2013 to commercialise ground-breaking technological advances developed over more than ten years at the Biomedical Ultrasonics, Biotherapy and …See details»
OxSonics Therapeutics - Crunchbase Company Profile & Funding
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development …See details»
OxSonics Therapeutics - LinkedIn
As 2023 comes the end, I want to reflect on main 2023 achievements at OxSonics under a refocused, leaner and more agile people organization. Kudos to the entire OxSonics crew for these great ...See details»
Contact - OxSonics Therapeutics
OxSonics’ proprietary intellectual property portfolio consists of multiple patent families and a substantial body of know-how that collectively provide protection to several key elements of …See details»
OxSonics Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development …See details»
OxSonics Therapeutics Company Profile 2024: Valuation, Funding ...
OxSonics Therapeutics General Information Description. Operator of a biotechnology company intended to develop anti-cancer therapy to enhance the delivery of anti-cancer agents to …See details»
OxSonics Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
OxSonics Therapeutics - Contacts, Employees, Board Members
Organization. OxSonics Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of …See details»
OxSonics Company Profile - Office Locations, Competitors ... - Craft
OxSonics has 5 employees at their 1 location, $16.05 m in total funding, and £13.21 k in annual revenue in FY 2016. See insights on OxSonics including office locations, competitors, …See details»
OxSonics raises £9.4m in series B equity financing
Jan 9, 2017 OxSonics, an Oxford University spinout established in 2013 to develop ultrasound therapeutics, has secured £9.4m in series B equity financing, bringing its total external …See details»
Oxsonics - Products, Competitors, Financials, Employees, …
OxSonics is a clinical-stage therapeutics company that develops a platform technology aimed at enhancing the delivery of anti-cancer drugs within the oncology sector. Its primary offering, the …See details»
OxSonics CEO, Jérôme Marzinski, gives ... - OxSonics Therapeutics
Jan 3, 2023 OxSonics Therapeutics: Jérôme Marzinski, Chief Executive Officer +44 (0)1865 784777 : Walbrook PR (media enquiries)Stephanie Cuthbert / Phillip Marriage +44 (0) 20 7933 …See details»
First Patient Dosed in Ground-Breaking Clinical Investigation for ...
Oxford, UK – 5th January 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, today announced that the …See details»
OxSonics Announces Clinical Data Showing SonoTran is Safe
Jan 23, 2023 OxSonics Therapeutics, a clinical-stage medtech company focused on transforming cancer treatment through SonoTran, its proprietary ultrasound-based drug …See details»
OxSonics bags $11M to take ultrasound tech into the clinic
Jan 9, 2017 OxSonics and its sister company have raised $11 million to take ultrasound-based technologies into clinical development. The Series B will support development of technology …See details»
Jérôme Marzinski appointed as Chief Executive Officer
Nov 7, 2022 Seasoned medtech leader with a proven track record in scaling companies Oxford, UK – 7 November 2022 – OxSonics Therapeutics, a clinical-stage company focused on …See details»
OxSonics - Oxford Investment Consultants portfolio Biotech …
OxSonics Therapeutics was spun out from the Institute of Biomedical Engineering at the University of Oxford in 2014. The Company’s proprietary platform technology, SonoTran ®, is …See details»
OxSonics Raises £10.5m in Oversubscribed ... - OxSonics …
Jul 3, 2020 OxSonics ® Raises £10.5m in Oversubscribed Series B2 Equity Financing. Oxford, UK – 1 st July 2020 – OxSonics Therapeutics, a world leader in the development of ultrasound …See details»
News, Media & Events - OxSonics Therapeutics
Oct 25, 2022 OxSonics’ proprietary intellectual property portfolio consists of multiple patent families and a substantial body of know-how that collectively provide protection to several key …See details»